Land: USA
Språk: engelsk
Kilde: NLM (National Library of Medicine)
AMMONIA N-13 (UNII: 9OQO0E343Z) (AMMONIA N-13 - UNII:9OQO0E343Z)
Cardinal Health 414, LLC
AMMONIA N-13
AMMONIA N-13 37.5 mCi in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Ammonia N-13 Injection, USP is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. None Animal reproduction studies have not been conducted with Ammonia N-13 Injection, USP. It is also not known whether Ammonia N-13 Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ammonia N-13 Injection, USP should be given to a pregnant woman only if clearly needed. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from Ammonia N-13 Injection, USP, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for N-13 isotope) after administration of the drug or avoid use of the drug, taking
Ammonia N-13 Injection, USP is packaged in 10 mL multiple dose glass vial containing between 1.11–11.1 GBq (30–300 mCi/mL) of [13 N] ammonia, at the end of synthesis (EOS) reference time, in 0.9% sodium chloride injection solution in approximately 8 mL to 10 mL volume. The recommended dose of radioactivity (10-20 mCi) is associated with a theoretical mass dose of 0.5-1.0 picomoles of Ammonia. NDC 65857-200-10 Storage Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Use the solution within 60 minutes of the End of Synthesis (EOS) calibration.
Abbreviated New Drug Application
AMMONIA N-13- AMMONIA N-13 INJECTION CARDINAL HEALTH 414, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE AMMONIA N-13 INJECTION, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR AMMONIA N-13 INJECTION, USP. AMMONIA N-13 INJECTION, USP FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2007 INDICATIONS AND USAGE Ammonia N-13 Injection, USP is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease (1). DOSAGE AND ADMINISTRATION Rest Imaging Study (2.1): • • Stress Imaging Study (2.2): • • • • Patient Preparation (2.3): • DOSAGE FORMS AND STRENGTHS Glass vial containing 0.138-1.387 GBq (3.75-37.5 mCi/mL) of Ammonia N-13 Injection, USP in aqueous 0.9 % sodium chloride solution (approximately 8 mL to 10 mL volume) (3). CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS Ammonia N-13 Injection, USP may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker (5). ADVERSE REACTIONS No adverse reactions have been reported for Ammonia N-13 Injection, USP based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting system (6). TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT CARDINAL HEALTH AT 1-800-618-2768 OR FDA AT 1-800- FDA-1088 OR WWW.FDA.GOV/MEDWATCH USE IN SPECIFIC POPULATIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 7/2018 Aseptically withdraw Ammonia N-13 Injection, USP from its container and administer 10-20 mCi (0.368 – 0.736 GBq) as a bolus through a catheter inserted into a large peripheral vein. Start imaging 3 minutes after the injection and acquire images for a total of 10-20 minutes. If a rest imaging study is performed, begin the stress imag Les hele dokumentet